Could a diabetes drug help teens with rare obesity syndromes shed pounds?

NCT ID NCT06901245

Recruiting now Disease control Sponsor: Grace Kim Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests tirzepatide, a weight loss medication, in 36 young adults aged 18-26 with obesity from Prader-Willi syndrome, hypothalamic obesity, or general causes. Participants take the drug for 48 weeks to see how much weight they lose and how their health changes. The goal is to find if tirzepatide works as well for genetic or brain-injury-related obesity as it does for common obesity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tirzepatide
What this could lead to: If it works, this could point toward a weight management option for young adults with hard-to-treat obesity due to genetic or brain injury causes.
What could go wrong: This is a small, early-phase study with only 36 participants, so results may not apply widely. Tirzepatide may cause side effects like nausea or vomiting, and weight loss may not be sustained long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOTHALAMIC OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired hypothalamic obesity Obesity obesity disorder Prader-Willi syndrome Sexual Infantilism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPOTHALAMIC OBESITY OBESITY/THERAPY PRADER-WILLI SYNDROME

Contacts and locations

Locations

Children's Minnesota
RECRUITING

Saint Paul, Minnesota, 55102, United States
Seattle Children's Hospital
RECRUITING

Seattle, Washington, 98105, United States
Vanderbilt University Medical Center
RECRUITING

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.